Rauma Marine Constructions: The First Multi-Purpose Corvette Built at Rauma Shipyard Has Been Launched
21.5.2025 15:51:00 CEST | Business Wire | Press Release
The first multi-purpose corvette built for the Finnish Navy’s pivotal Squadron 2020 project was launched at Rauma shipyard on Wednesday 21 May 2025. This is a significant milestone and an indication of RMC’s ability to successfully realise demanding building projects.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250521270211/en/
The first multi-purpose corvette built for the Finnish Navy’s pivotal Squadron 2020 project was launched at Rauma shipyard in Finland on Wednesday 21 May 2025. Photo by Rauma Marine Constructions.
The Squadron 2020 project is proceeding on schedule. The building pace will accelerate as work on the second and subsequent multi-purpose corvettes progresses. The direct employment impact of the Squadron project in Finland is equivalent to more than 3,600 person-years.
“We have increased the capacity of Rauma shipyard purposefully while strategically implementing significant investments in the shipyard area. Rauma shipyard is now in peak condition”, says Mika Nieminen, CEO of RMC.
RMC’s capability is based on excellent engineering expertise, capable project management and a commitment to delivering complex and high-quality vessels. The ability to build different types of ships from high-efficiency commercial vessels to warships and icebreakers designed for extreme conditions emphasises RMC’s extensive technical expertise and adaptability.
“The newly launched vessel is a strong indication of the close and goal-oriented co-operation between the Finnish Government, the Finnish Defence Forces, the Finnish Defence Forces Logistics Institute, the Finnish Navy, Rauma Marine Constructions, Saab and all our industrial partners”, states Timo Ståhlhammar, Project Director of RMC’s Squadron Project.
RMC will be building a total of four Pohjanmaa-class multi-purpose corvettes for the Finnish Navy. The Pohjanmaa class is one of the most capable vessel types operating in the Baltic Sea region. They are designed to operate year-round in all Baltic Sea conditions.
Significant investments have been made in Rauma shipyard throughout the 2020s to strengthen the shipyard’s shipbuilding infrastructure and independent production capacity. The closed multi-purpose hall designed for the construction of the multi-purpose corvettes ensures good working conditions, high quality results and the implementation of the required safety measures. In addition, investments have been made in steel production, a launching barge and heavy transfer ramps.
“The building of these corvettes will advance the shipbuilding industry and technological know-how in Finland. RMC is ready to utilise the capabilities acquired through the Squadron 2020 project both in Finland and internationally”, says Mika Nieminen, CEO of RMC.
Key dimensions of the multi-purpose corvettes:
Length: 117 m
Beam: 16.5 m
Draught: 5 m
Crew: 70
View source version on businesswire.com: https://www.businesswire.com/news/home/20250521270211/en/
Contacts
Media inquiries:
Rauma Marine Constructions Oy
Hanna-Kaisa Koskinen
hanna-kaisa.koskinen@rmcfinland.fi
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press Release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP alone as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. The oral presentation of these data is taking place at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29 – June 2, 2026, in Chicago (Abstract #LBA7000. Session: Oral Abstract Session – Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia. May 30, 4:00 – 7:00 p.m. ET [3:00 – 6:00 p.m.
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press Release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press Release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press Release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press Release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom